Related Experiment Video
Updated: May 18, 2026
07:51
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Personalized cardiovascular medicine: status in 2012
Sonny Dandona1, Robert Roberts
1Department of Medicine, McGill University, Montreal, Quebec, Canada.
The Canadian Journal of Cardiology
|October 6, 2012
Summary
Genetic testing can personalize antiplatelet, warfarin, and statin therapies. While clopidogrel genetic testing shows promise, other pharmacogenetic tests are still under investigation for routine use.
Area of Science:
- Pharmacogenetics and Personalized Medicine
- Genetics and Drug Metabolism
- Clinical Pharmacology
Background:
- Personalized medicine tailors healthcare to individual patient characteristics.
- Genetic variations significantly impact drug response and efficacy.
- Current drug therapy models often follow a "one-size-fits-all" approach.
Purpose of the Study:
- To review the current status of genetic variants influencing antiplatelet agents, warfarin, and statin therapies.
- To highlight the potential of pharmacogenetics in customizing drug treatment.
- To discuss the implications of genetic testing in clinical practice.
Main Methods:
- Review of existing literature on pharmacogenetics and drug response.
- Analysis of genetic variants affecting clopidogrel, warfarin, and statin metabolism and efficacy.
- Discussion of the clinical utility and controversies surrounding genetic testing.
Main Results:
- Genetic resistance to clopidogrel (an antiplatelet) is prevalent, particularly in Asian populations, linked to the CYP2C19*2 allele.
- Point-of-care genetic testing for clopidogrel is a recent advancement with potential for personalized medicine.
- Genetic testing for aspirin resistance is not yet recommended; studies on warfarin genetic testing are ongoing.
- SLCO1B1 allele testing for statin-induced muscle cramps is potentially useful but not routine.
Conclusions:
- Pharmacogenetics offers the potential to move beyond a "one-drug-fits-all" model towards customized patient therapy.
- Further research and clinical validation are needed for widespread adoption of pharmacogenetic testing.
- Genetic insights are crucial for optimizing drug selection and dosage for improved patient outcomes.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...